firstwordpharmaAugust 23, 2021
Vividion Therapeutics withdrew its plans for an initial public offering after announcing earlier this month that it would be acquired by Bayer for up to $2 billion, Renaissance Capital reported.
The company was founded in 2013 and had disclosed plans in June to raise $100 million and list on the Nasdaq under the symbol VVID.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: